The FTC has cleared GlaxoSmithKline's deal with Synta, paving the way for Synta to receive an $80 million dollar up-front payment. Back in October GSK and Synta inked a $1.1 billion deal for STA-4783, which has demonstrated efficacy in improving median survival rates for melanoma patients in a mid-stage study. Synta was a 2004 Fierce 15 company. Report